CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...